Edison issues flash on Agronomics (ANIC)
RNS Number : 6052A
London, UK, 26 September 2022
Edison issues flash on Agronomics (ANIC)
Agronomics (ANIC) invests in cellular agriculture companies. In our last note, we discussed a shift in its focus more towards precision fermentation companies, whose development is more advanced, offering greater near-term commercial potential. This week’s announcement that Onego Bio, one of ANIC’s portfolio companies, has entered a partnership with Perfect Day, a US precision fermentation company, is a further step in this direction. The alliance should hasten Onegro Bio’s route to market and financial viability and increase ANIC’s potential to realise further NAV uplifts. Food giant Nestlé’s recent move into precision fermentation is further evidence that ANIC’s increasing interest in this sector may prove timely.
News of Onego Bio’s alliance with Perfect Day closely follows another announcement that bodes well for the future of precision fermentation technology more generally, and for ANIC’s increasing investment in this sector. Last week, Nestlé announced it is exploring emerging technologies for the development of animal-free dairy protein-based products. Nestlé’s interest in fermentation technology demonstrates the attraction this technology has as a potentially viable method of producing animal-free protein at scale. Specifically, Nestlé will pilot a novel product that uses animal-free protein produced by Perfect Day. The product will be tested in the US market later this year. Further details about this product are not yet available, but its development will be supported by Nestlé’s R&D Accelerator programme, which brings together start-ups, academic institutions and Nestlé scientists with the purpose of accelerating the development of new products and systems. Programme participants have access to Nestlé’s R&D expertise and its infrastructure, including labs, kitchens and pilot-scale equipment.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Joanne Collins +44 (0)20 3077 5700 email@example.com
Sara Welford +44 (0)20 3077 5700 firstname.lastname@example.org
Learn more at www.edisongroup.com and connect with Edison on:
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK
regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange